Importantly, by depending on the mutant cysteine residue for binding, the compounds specifically target the KRASG12C mutant protein while sparing KRAS wild-type protein, an observation supported by the selectively inhibition of growth of cancer cell lines expressing KRASG12C. Here, KRAS is linked to cancer.